The first two authors contributed equally to this work Common variable immunodeficiency (CVID) is a primary immune disorder characterized by impaired antibody production, which is in many instances secondary to defective T cell function (T-CVID). We previously identified a subset ofT-CVID patients characterized by defective expression of Vav1, a guanine nucleotide exchanger which couples the T-cell antigen receptor to reorganization of the actin cytoskeleton. Here we have addressed the possibility that an intrinsic defect in the Vav1 gene might underlie the reduction in Vav protein observed in T cells from these patients. We report the identification in one T-CVID patient of a heterozygous deletion in Vavl. The gene deletion, spanning exons 2-27, accounts for the reduction in Vavl mRNA and protein in T cells from this patient. The disease-related pedigree of this patient suggests a de novo origin of the Vavl deletion. The findings highlights Vavl as an autosomal dominant disease gene associated with CVID with defective T-cell function.
Common variable immunodeficiency (CVID) is a primary immune disorder encompassing a heterogenous group of diseases whose unifying feature is hypogammaglobulinemia. As a consequence of the impairment in antibody production, CVID patients suffer from recurrent pyogenic sinopulmonary infections and are prone to autoimmune and malignant disorders (1, 2) . Major progress towards elucidating CVID has been achieved with the identification of defects not only in B-cells, which are directly responsible for antibody production, but also in other immune cells implicated in the generation of an effective humoral response, including antigen-presenting cells and, in a significantproportion ofthese patients, helper T cells (3, 4) .
In CVID patients with defective T-cell function (T-CVID), decreased proliferative responses to mitogens, impaired cytokine production and defective expression of activation markers have been observed (3, 4) . To date, the genetic basis of these defects has been established only for a subset of T-CVID patients, characterized by the homozygous loss ofICOS, an inducible costimulator expressed on activated T cells (5) . While distinct genetic lesions affecting different stages of T-cell activation and differentiation may all result in T-cell dysfunction, defects in the molecular machinery which controls initiation of T cell antigen receptor (TCR) signaling could account for many of the abnormalities described in T-CYID. Impairment of early signaling events, such as calcium mobilization and phospholipid breakdown, has indeed been reported in a subset ofT-CYID patients (6, 7) . Furthermore, a decrease in the levels of the protein tyrosine kinase Lck, resulting from aberrant splicing of the gene transcript, has been described in one T-CYID patient (8) .
We previously identified a subset of four T-CYID patients characterized by defective activation of the protein tyrosine kinase cascade triggered by TCR engagement (9, 10) . In these patients T cells harbour a profound defect in the Vav/Rac pathway controlling reorganization of the actin cytoskeleton (II), an intracellular process crucially required for the formation and stabilization of the signaling platform which forms at the interface between T cell and antigen-presenting cell, known as immunological synapse (12) . The impairment in F-actin reorganization was found to be linked to a deficiency in the Rae guanine nucleotide exchanger, Vav (13) , which in three out of four T-CYID patients was associated with reduced Vavl mRNAlevels (II). This defect could be rescued by VavI reconstitution, supporting a causal role of Vavl deficiency in the disease. This implication has been recently further strengthened by our finding that differentiation ofTh2 cells, which are essential for optimizing the antibody response, is impaired in these patients (14) , similar to Vavl" mice (15) . Here we have investigated the potential role of epigenetic modification or genetic lesions in either the Vav1 promoter or the gene itself in the defective Vav1 expression observed in these patients.
MATERIALS AND METHODS

Patients
Patients were classified as CVID according to WHO classification of primary immunodeficiencies. Controls were sex-and age-matched healthy volunteers. Peripheral blood was obtained after informed consent and sample size was kept small according to the guidelines of the ethics committee. All clinical investigation was conducted according to the principles expressed in the Declaration of Helsinki. No overt infectious disease was present at the time of blood sampling. Peripheral blood mononuclear cells were isolated from whole blood by density centrifugation on Ficoll-Hypaque (Amersham Biosciences Europe, Milan, Italy) and subsequently depleted of monocytes by adherence.
DNA purification, genome bisulfate sequencing, Vavl exon sequencing
Genomic DNA was extracted from peripheral blood lymphocytes of four CVID patients with defective activation of the TCR protein tyrosine kinase cascade (T-CVIDl, T-CVID2, T-CVID3, T-CVID4) (7, 8) , two CVID patients with normal T-cell function (disease controls) (10, 11) , and two healthy controls, using the QIAamp DNA minikit (Qiagen SpA, Milan, Italy). DNA extraction from the biopsy was performed from 20 urn slices of paraffin-embedded sample treated with Lysis Buffer and Proteinase K at 56°C overnight. After removal of the paraffin, DNAwas extracted using the QIAamp DNA minikit (Qiagen SpA, Milan, Italy). DNA was subjected to sodium bisulfite treatment and subsequent desulfonation as described (16) . Following ethanol precipitation, DNA was subjected to PCR using the GoTaq DNA polymerase (Promega) and primers designed to amplify the Vavl enhancer region. The PCR products were cloned in the pCR2.1-Tapa vector, plasmid DNA was recovered from individual colonies and subjected to automated sequencing. At least 10 clones from independent PCR products were sequenced for each donor.
The 27 Vavl exons and the respective flanking regions were amplified from genomic DNA by PCR. PCR products were subjected to automatic sequencing using an ABI PRISM 310 genetic analyzer (PE Applied Biosystems, Foster City, CA, USA).
Real-time quantitative peR
Real-time quantitative PCR was performed using pre-designed sets of primers and probes specific for Vavl provided by the Assay-by-Design service (Applied Biosystems, Foster City, CA). Primers and probes were designed in exons 1,2,6, 7 and 27 of the gene, as well as in the promoter region ( Fig.lA) (11, 14) . PCR was carried out using an ABI prism 7000 (Applied Biosystems) in a 96-well optical plate with a final reaction volume of 50 ml. PCR reactions were prepared from a single mix consisting of: 2X TaqMan Universal PCR Master Mix, 20X Vavl Assay Mix, 20X RNAaseP Mix (internal reference) and HPLC pure water. A total of 100 ng of DNA was dispensed in each of the four sample wells for quadruplicate reactions. Thermal cycling conditions included a pre-run of 2 min at 50°C and 10 min at 95°C. Cycle conditions were 40 cycles at 95°C for 15 sand 60°C for 1 min, according to the TaqMan Universal PCR Protocol (Applied Biosystems). Control samples were used for the purpose of calibration. The starting copy number of the unknown samples was determined using the comparative Ct method, as previously described (17) .
Cytokine production CD4+ T cells were activated by anti-CD3 mAb (OKT3) for 36h and cytokine production was investigated in the supernatants of both T-CVID patients and controls. Cytokines were measured by ELISA (Biosource international). CD4+ cells from Vavl-deficient patients with CVID were significantly impaired in their ability to produce IL-4 (mean±SD, 307±l05 pg/mL) compared with controls The amount ofIFN-g (mean±SD, 1,850±14l pg/ mL) produced by cells from Vavl-deficient patients with CVID was significantly higher than that found in controls.
RESULTS
We have previously described four CVID patients with impaired T cell responses to TCR agonists sharing a defect in Vav1 expression. The reduction in Vav protein correlated with a reduction in Vav1 mRNA in three out of the four patients (11) . The possibility that epigenetic promoter modification or an impairment in one Vav1 allele might underlie the reduction in Vavl mRNA in these patients was addressed. Specifically, we searched for Vav1 promoter methylation, point mutations and gene deletions.
The defect in Vav1 expression in the four T-CVID patients is not caused by promoter mutations or epigenetic silencing
Aberrant promoter methylation has emerged as a major cause of alterations in gene expression in a wide variety of diseases (18) . Expression of Vav1 is restricted to hematopoietic cells (13) , where it is regulated by stage-and tissue-specific transcriptional activators. A short region upstream of the coding sequence, spanning positions -312 to +137 and containing a CpG island, has been identified as necessary and sufficient for tissue-specific expression (19) . To assess the potential contribution of CpG methylation to the defect in Vav1 expression in the three T-CVID patients with reduced Vav1 mRNA levels (T-CVIDl, T-CVID2, T-CVID4), genomic DNA was purified from peripheral T cells from these patients, as well as from the patient with normal Vavl mRNA levels (T-CVID3), one disease control and two healthy controls. DNA was treated with sodium bisulfate and a fragment encompassing positions -312 to +137 of Vavl amplified by PCR. The amplification product was cloned, and at least 10 clones were sequenced for each sample. No methylation in any of the 16 cytosines included in CpG island was found in any sample (Fig. 1A) , ruling out promoter methylation as the cause ofthe defect in Vav1 expression in patients T-CVIDI, T-CVID2 and T-CVID4. Furthermore, real-time PCR analysis on genomic DNA from these patients using a TaqMan probe specific for the promoter region ( Fig. IB) , as well as automatic sequencing of the promoter, ruled out both a deletion in one allele and point mutations in the Vav1 gene promoter in these patients.
The defect in Vav1 expression is caused by Vav1 haploinsufficiency in one ofthe four T-CVID patients
Alternative intrinsic defects in the Vav1 gene which could result in an expression defect include point mutations in the coding sequence or in the splice sites, or a deletion in one of the two alleles. Sequence analysis of all Vav1 exons and the respective flanking regions, carried out on PCR fragments amplified from genomic DNA from patients T-CVIDI, T-CVID2 and T-CVID4, did not reveal any mutation. The possibility that a deletion in one Vav1 allele might underlie the expression defect in patients T-CVID1, T-CVID2 and T-CVID4 was assessed by real-time quantitative PCR. Patient T-CVID3, two disease controls and two healthy donors were included in the analysis. The results revealed the presence of a heterozygous Vav1 deletion in patient T-CVID1. The deletion spans exons 2 to 27 of the Vavl gene (Fig. IB) . The Vavl deletion, which includes the polyadenylation site, is predicted to result in the production of a truncated highly unstable primary transcript.
The proband is a 72-year-old Italian woman with hypogammaglobulinemia (319 mg/dl vs 643-1488 mg/dl in healthy donors) who, from the age of 32, had suffered from recurrent gastrointestinal, genitourinary and sinopulmonary infections leading to medial segment of right middle lobe bronchiectases, treated by antibiotics and intravenous immunoglobulin administration. She also suffered from severe osteoporosis and colon diverticulitis. Vavl mRNA level reduced reduced normal reduced a)Age-and disease-matched controls have been described previously (11) .
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Additional serological and immunophenotypical data on the patient, as well as on the other patients with defective Vavl expression, are shown in Table  1 . The father of patient T-CVID1 died at the age of 68 from pulmonary emphysema after recurrent sinopulmonary infections. These clinical findings could be consistent with a diagnosis of CVID. Realtime quantitative PCR on genomic DNA extracted from a stored gastric biopsy using TaqMan probes specific for the Vav1 promoter and exon 1 showed normal values, as expected. At variance with patient T-CVID 1, normal values were however found also for exons 2, 7 and 27, ruling out the presence of the Vav1 deletion in the father of the proband ( Fig. 2A and data not shown). The same applies to the 44-year old daughter and 40-year old son ofthe proband, who are both healthy and with normal immunoglobulin values. Recurrent infections are not reported for the mother, who died at the age of93. While this does not rule out that the proband inherited the Vav1 deleted allele from the mother, the clinical history suggests that the mutation is likely to have arisen de novo in the proband.
DISCUSSION
Collectively, the results show that a genetic impairment in the Vav1 gene is the cause of the reduction in Vav1 mRNA in T cells from one of the four T-CVID patients with defective Vav expression identified in our previous study.Although some degree of redundancy has been found among the three Vav family members in the mouse (20) , Vav1 is crucially required for not only for T-cell activation, but also for helper T-cell differentiation to the Th2 subset, as demonstrated by the defects observed in T cells from Vav1-1 -mice (15, 21) . In this respect, it is noteworthy that TCR clustering and F-actin accumulation at the immunological synapse are impaired in mice heterozygous for a Vav1 null mutation (22). Our finding that, notwithstanding the presence of normal levels ofVav2 and Vav3 mRNA, a selective reduction in Vav1 expression is sufficient to impair F-actin reorganization and T cell activation (11) , as well as Th2 cell differentiation (14) , in our T-CVID patients underlines the importance of Vav1 gene dosage in T cells not only in the mouse, but also in humans.
The fact that an intrinsic defect in the Vav1 gene was found in only one out of the four T-CVID analyzed in this study, who all share a reduction in Vav expression in peripheral T cells, further underlines the heterogeneity of this disease. Distinct genetic impairments, affecting for example the transcriptional machinery which controls Vav1 expression, may be responsible for the impairment' in Vav1 expression. When considering patient CVID-3, the Vav1 protein expression is reduced but with a normal level of Vav1 mRNA, suggesting a down-regulation at the translational level, may be via proteosomal degradation (23, 24) . Nevertheless, the identification of Vav1 haploinsufficiency in one T-CVID patient, albeit likely of de novo origin, indicates that Vav1 is a new disease gene in T-CVID and should be included in the genetic analysis of CVID patients. It should be underlined that, while we have focused on CVID patients with defective T-cell function, Vav1 is also implicated in BCR signaling (25) , suggesting that Vav1 could represent a candidate disease-gene also in CVID patients with B cell defects.
In summary, the data presented in this report identify for the first time a mutation in the human Vav1 gene resulting in haploinsufficiency and implicate Vav1 as a disease gene associated with autosomal dominant CVID with defective T-cell function.
